首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 编委会 => 常务编委 => 今関 文夫
今関 文夫
Associate Professor
日本千叶大学大学院医学研究院消化器内科
研究方向:
  
病毒性肝炎的治疗和肝细胞癌的发病机制。
发表论文及科研的基本情况(近五年):
1.Matsumura T, Arai M, Yonemitsu Y, Maruoka D, Tanaka T, Suzuki T, Yoshikawa M, Imazeki F, Yokosuka O. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol. 2010 Mar;45(3):300-7.
2.Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010 Feb 6;4(1):414-22.
3.Tada M, Kanai F, Tanaka Y, Sanada M, Nannya Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Imazeki F, Yoshida H, Ogawa S, Yokosuka O, Omata M. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010 Jan 19.
4.Ito K, Arai M, Imazeki F, Yonemitsu Y, Bekku D, Kanda T, Fujiwara K, Fukai K, Sato K, Itoga S, Nomura F, Yokosuka O. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol. 2010;45(2):243-9.
5.Kanda T, Gauss-Müller V, Cordes S, Tamura R, Okitsu K, Shuang W, Nakamoto S, Fujiwara K, Imazeki F, Yokosuka O. Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein. J Viral Hepat. 2009 Nov 2.
6.Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol. 2009 Oct 23.
7.Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A, Yokosuka O. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol. 2009 Sep;40(9):1304-11.
8.Maruyama H, Ishibashi H, Takahashi M, Imazeki F, Yokosuka O. Effect of signal intensity from the accumulated microbubbles in the liver for differentiation of idiopathic portal hypertension from liver cirrhosis. Radiology. 2009 Aug;252(2):587-94.
9.Fujiwara K, Kojima H, Yonemitsu Y, Yasui S, Imazeki F, Miki M, Suzuki K, Sakaida I, Okita K, Tanaka E, Omata M, Yokosuka O. Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities. Liver Int. 2009 Jul;29(6):838-45.
10.Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol. 2009 Feb;24(2):255-61.
11.Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, Kanai F, Imazeki F, Yokosuka O. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol. 2009;44(7):872-7.
12.Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol. 2008 Sep;23(9):1320-6.
13.Arai M, Imazeki F, Sakai Y, Mikata R, Tada M, Seki N, Shimada H, Ochiai T, Yokosuka O. Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2'-deoxycytidine, in esophageal squamous cell carcinoma. Oncol Rep. 2008 Aug;20(2):405-12.
14.Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Muroyama R, Fukai K, Imazeki F, Kawabe T, Yokosuka O, Omata M. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 15;14(12):3768-76.
15.Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008 Mar;28(3):355-62.
16.Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S, Yokosuka O.  Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43(9):711-9.
17.Zhang KY, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci. 2007 Dec;98(12):1921-9.
18.Kanda T, Yokosuka O, Imazeki F, Hirasawa Y, Ikeuchi T, Mikata R, Zhang KY, Kurihara T, Arai M, Fukai K, Saisho H, Mikami S, Azemoto R, Ito Y. Body mass index in Japanese patients with autoimmune liver disease: overweight patients with primary biliary cirrhosis tend to be asymptomatic. Hepatogastroenterology. 2007 Sep;54(78):1758-60.
19.Tada M, Imazeki F, Fukai K, Sakamoto A, Arai M, Mikata R, Tokuhisa T, Yokosuka O. Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hepatol Int. 2007 Sep;1(3):355-64.
20.Fukai K, Zhang KY, Imazeki F, Kurihara T, Mikata R, Yokosuka O. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase. J Viral Hepat. 2007 Sep;14(9):661-6.
21.Fujiwara K, Yokosuka O, Imazeki F, Miki M, Suzuki K, Okita K, Tanaka E, Omata M. Analysis of hepatitis A virus protein 2B in sera of hepatitis A of various severities. J Gastroenterol. 2007 Jul;42(7):560-6.
22.Zhang K, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. J Med Virol. 2007 Jun;79(6):683-93.
23.Fujiwara K, Yokosuka O, Imazeki F, Miki M, Suzuki K, Okita K, Tanaka E, Omat M. Genetic analysis of hepatitis A virus protein 2C in sera from patients with fulminant and self-limited hepatitis A. Hepatogastroenterology. 2007 Apr-May;54(75):871-7.
24.Kanda T, Yokosuka O, Mikata R, Zhang KY, Tanaka M, Tada M, Fukai K, Imazeki F, Saisho H. Inhibition of subgenomic hepatitis C virus RNA replication in HeLa cells. Hepatogastroenterology. 2007 Jan-Feb;54(73):32-5.
25.Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, Shao RX, Dharel N, Tanaka Y, Ohta M, Tateishi R, Shiina S, Tatsukawa M, Fukai K, Imazeki F, Yokosuka O, Shiratori Y, Omata M. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol. 2006 Dec;45(6):805-12.
26.Mikata R, Yokosuka O, Fukai K, Imazeki F, Arai M, Tada M, Kurihara T, Zhang K, Kanda T, Saisho H. Analysis of genes upregulated by the demethylating agent 5-aza-2'-deoxycytidine in gastric cancer cell lines. Int J Cancer. 2006 Oct 1;119(7):1616-22.
27.Arai M, Yokosuka O, Hirasawa Y, Fukai K, Chiba T, Imazeki F, Kanda T, Yatomi M, Takiguchi Y, Seki N, Saisho H, Ochiai T. Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-Aza-2'-deoxycytidine. Cancer. 2006 Jun 1;106(11):2514-25.
28.Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, Tanaka N, Imazeki F, Shiratori Y, Arakawa Y, Omata M; Tokyo Hepatitis Network. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver Int. 2006 Jun;26(5):520-8.
29.Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Saisho H. Hepatitis A protein VP1-2A reduced cell viability in Huh-7 cells with hepatitis C virus subgenomic RNA replication. J Gastroenterol Hepatol. 2006 Mar;21(3):625-6.
30.Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Saisho H. Occurrence of autoimmune hepatitis during the course of primary biliary cirrhosis: report of two cases. Dig Dis Sci. 2006 Jan;51(1):45-6.
31.Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, Miyazaki M, Ochiai T, Saisho H, Yokosuka O. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology. 2006;71(1-2):77-85.
32.Arai M, Yokosuka O, Kanda T, Fukai K, Imazeki F, Muramatsu M, Seki N, Miyazaki M, Ochiai T, Hirasawa H, Saisho H. Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol. 2006 Jan;41(1):102-10.
33.Kanda T, Yokosuka O, Imazeki F, Arai M, Saisho H. Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol. 2005 Dec;24(12):805-9.
34.Fukai K, Yokosuka O, Imazeki F, Tada M, Mikata R, Miyazaki M, Ochiai T, Saisho H. Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma. Liver Int. 2005 Dec;25(6):1209-16.
35.Yokosuka O, Kawai S, Suzuki Y, Fukai K, Imazeki F, Kanda T, Tada M, Mikata R, Hata A, Saisho H. Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0. Liver Int. 2005 Dec;25(6):1136-41.
36.Chiba T, Yokosuka O, Goto S, Fukai K, Imazeki F, Kohno Y, Nishimura M, Saito Y, Saisho H. Clinicopathological features in patients with hepatic graft-versus-host disease. Hepatogastroenterology. 2005 Nov-Dec;52(66):1849-53.
37.Kanda T, Tada M, Imazeki F, Yokosuka O, Nagao K, Saisho H. 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol Rep. 2005 Oct;14(4):975-9.
38.Imazeki F, Yokosuka O, Fukai K, Kawai S, Kanda T, Kojima H, Saisho H. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005 Aug;25(4):772-8.
39.Hoshida Y, Kato N, Yoshida H, Wang Y, Tanaka M, Goto T, Otsuka M, Taniguchi H, Moriyama M, Imazeki F, Yokosuka O, Kawabe T, Shiratori Y, Omata M. Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. J Infect Dis. 2005 Jul 15;192(2):266-75.
40.Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Suzuki Y, Saisho H. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005 Jul-Aug;52(64):1233-5.
41.Mikata R, Yokosuka O, Imazeki F, Fukai K, Kanda T, Saisho H. Prolonged acute hepatitis A mimicking autoimmune hepatitis. World J Gastroenterol. 2005 Jun 28;11(24):3791-3.
42.Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H.  Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol. 2005 Jun 14;11(22):3346-50.
43.Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Nagao K, Saisho H.Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun. 2005 Jun 3;331(2):621-9.
44.Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, Suzuki Y, Hata A, Saisho H. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005 Jun;100(6):1322-9.
45.Imamura T, Yokosuka O, Chiba T, Kanda T, Kojima H, Fukai K, Imazeki F, Nishimura M, Saito Y, Saisho H. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation. Leuk Lymphoma. 2005 Jun;46(6):915-7.
46.Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, Saisho H. Identification and investigation of methylated genes in hepatoma. Eur J Cancer. 2005 May;41(8):1185-94.
47.Tada M, Yokosuka O, Fukai K, Chiba T, Imazeki F, Tokuhisa T, Saisho H. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J Hepatol. 2005 Apr;42(4):511-9.
48.Fujiwara K, Yokosuka O, Imazeki F, Saisho H, Miki M, Omata M. Do high levels of viral replication contribute to fulminant hepatitis A? Liver Int. 2005 Feb;25(1):194-5.
49.Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005 Jan 18;142(2):105-14.
50.Kanda T, Yokosuka O, Hiraide A, Kojima H, Honda A, Fukai K, Imazeki F, Nagao K, Saisho H. Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan? Hepatogastroenterology. 2005 Jan-Feb;52(61):180-2.
地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号